Treatment with salidroside improves dyslipidemia and inhibits hepatic lipid deposition and attenuates NAFLD by modulating oxidative stress and inhibiting the TXNIP/NLRP3 pathway [73]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.